A Clinical Study Investigating the Effects of a Dentifrice Containing 67% Sodium Bicarbonate When Used Twice Daily for 12 Weeks on Gingivitis Treatment and Plaque Removal

Gingivitis Clinical Trial

Official title:

A Randomized, Controlled, Examiner-Blind Clinical Study Investigating the Effects of a Dentifrice Containing 67% Sodium Bicarbonate When Used Twice Daily for 12 Weeks on Gingivitis Treatment and Plaque Removal

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05654662
• Other study ID #: 300029
• Status: Completed
• Phase: N/A
• Start date: February 20, 2023
• Est. completion date: November 30, 2023

Study information

• Verified date: December 2023
• Source: HALEON
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The main goal of this study is to evaluate and compare the efficacy of an on-market dentifrice containing 67 percent (%) sodium bicarbonate and 0.31% sodium fluoride to a reference regular fluoride dentifrice on treating gingival bleeding and gingival inflammation as well as reducing plaque accumulation in population with gingivitis after 12 weeks use.

Description:

This will be a single center, controlled, single blind (examiner blind), randomized, two treatment arm, parallel study in volunteers with clinically measurable levels of gingivitis (defined as those with 10-30% bleeding sites on probing). Approximately 200 participants (100 per group) will be randomized to ensure 188 evaluable participants (94 per group) complete the study.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 204
• Est. completion date: November 30, 2023
• Est. primary completion date: November 30, 2023
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Participant provision of a signed and dated informed consent document indicating that the Participant has been informed of all pertinent aspects of the study before any assessment is performed.

• Participant who is willing and able to comply with scheduled visits, treatment plan, and other study procedures.

• A Participant in good general and mental health with, in the opinion of the investigator or medically qualified designee, no clinically significant/relevant abnormalities in medical history or upon oral examination, or condition, that would impact the Participant's safety, wellbeing or the outcome of the study, if they were to participate in the study, or affect the individual's ability to understand and follow study procedures and requirements.

• Participant oral health that meets all the following:

At Screening (Visit 1):

1. Participant with at least 20 natural, permanent teeth.

2. Participant with at least 40 evaluable surfaces for MGI, BI, and TPI (An evaluable surface is defined as having 2/3rds of the natural tooth surface gradable for the selected clinical indices. The following should not be included in the evaluable surface count- third molars; fully crowned/extensively restored, grossly carious, orthodontically banded/bonded or abutment teeth; surfaces with calculus deposits which, in the opinion of the clinical examiner, would interfere with the baseline assessments of the selected clinical indices).

3. A participant with plaque-induced gingivitis, in the opinion of the clinical examiner, as confirmed by a gross visual examination at the Screening Visit.

At Baseline (Visit 2):

1. A participant with ongoing hard tissue eligibility and, in the opinion of the clinical examiner, at least 40 evaluable surfaces.

2. A participant with 10% less than (<) bleeding on probing (BOP) < 30%.

3. A participant with mean whole mouth TPI score more than or equal to (>=)1.5.

Exclusion Criteria:

• A participant who is an employee of the investigational site, either directly involved in the conduct of the study or a member of their immediate family; or an employee of the investigational site otherwise supervised by the investigator; or, a sponsor's employee directly involved in the conduct of the study or a member of their immediate family.

• A participant who has participated in other studies (including non-medicinal studies) involving investigational product(s) within 30 days prior to study entry and/or during study participation.

• A participant with, in the opinion of the investigator or medically qualified designee, an acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator or medically qualified designee, would make the participant inappropriate for entry into this study.

• A participant who has any other clinical serious or unstable conditions (such as, cardiovascular diseases, diabetes, liver disorders, and kidney disorders) which could have affected study out comes and/or participant safety.

• A participant who is a pregnant female (self-reported) or is intending to become pregnant over the duration of the study.

• A participant who is a breastfeeding female.

• A participant who is known or suspected intolerance or hypersensitivity to the study materials (or closely related compounds) or any of their stated ingredients.

• A participant who is unwilling or unable to comply with the lifestyle considerations.

• Participant who is a current smoker or an ex-smoker who stopped within 6 months of Screening.

• Participant who is using smokeless forms of tobacco (such as, chewing tobacco, gutkha, pan containing tobacco, nicotine-based e-cigarettes).

• A participant who is diagnosed xerostomia or is taking any medication that in the view of the investigator is causing xerostomia.

• A participant who has a medical condition which could have directly influenced gingival bleeding.

• A participant who has a bleeding disorder that could have affected study outcomes and/or participant safety.

• A participant who has a recent history (within the last year) of alcohol or other substance abuse.

• A participant who has a severe oral condition (such as, acute necrotizing ulcerative gingivitis or oral or peri-oral ulceration including herpetic lesions) that could, in the opinion of the investigator, compromise study outcomes or the oral health of the participant/examiner if they participate in the study.

• Presence of a tongue or lip piercing, or any other oral feature that could interfere with the usage of a toothbrush.

Medication Exclusions At Screening (Visit 1):

1. A participant using any antibiotic medication within 14 days prior to screening or at any time during the study.

2. A participant currently taking an anti-inflammatory medication which, in the opinion of the Investigator, could affect gingival condition.

3. A participant currently taking a systemic medication (such as, anti-inflammatory, anticoagulant, immunosuppressants) or traditional/ herbal remedy which, in the opinion of the Investigator, could affect plaque/ gingival condition (such as, ibuprofen, aspirin, warfarin, cyclosporin, phenytoin, calcium channel blockers).

Medication Exclusions at Baseline (visit 2):

1. A participant who has taken (in the previous 14 days), any antibiotics.

2. A participant who has taken (in the previous 14 days) a systemic medication (such as, anti-inflammatory, anti-coagulant, immunosuppressants) or traditional/ herbal remedy which, in the opinion of the Investigator, could affect plaque/ gingival condition (such as, ibuprofen, aspirin, warfarin, cyclosporin, phenytoin, calcium channel blockers).

3. A participant who has used an antibacterial dentifrice or mouthwash (such as, chlorhexidine) or any oral care product that in the view of the investigator could interfere with plaque formation or measures of gingivitis, in the period between Screening and the Baseline visit.

Periodontal Exclusions

1. A participant who shows signs of periodontitis (one or more sites with probing pocket depths more than [>] 3 mm).

2. A participant who is receiving or has received treatment for periodontal disease (including surgery) within 12 months of Screening.

3. A participant who has gingivitis, which in the opinion of the investigator, is not expected to respond to treatment with an over the counter (OTC) dentifrice.

Dental Exclusions

1. A participant who has active caries that could, in the opinion of the investigator, compromise study outcomes or the oral health of the participant if they participate in the study.

2. A participant who has dentures (partial or full).

3. A participant who has an orthodontic appliance (bands, appliances, or fixed/ removable retainers).

4. A participant who received orthodontic therapy within 3 months of Screening.

5. A participant who has numerous restorations in a poor state of repair.

6. A participant who has any dental condition (such as, overcrowding) that could, in the opinion of the investigator, compromise study outcomes or the oral health of the participant if they participate in the study.

7. A participant who has had dental prophylaxis within 12 weeks of Screening.

8. A participant who has had teeth bleaching within 12 weeks of Screening.

9. A participant who has high levels of extrinsic stain or calculus deposits, in the opinion of the investigator, that could have interfered with plaque assessments.

10. A participant who has previously been enrolled in this study.

11. A participant who, in the opinion of the investigator or medically qualified designee, should not participate in the study.

Related Conditions & MeSH terms

• Dental Plaque
• Gingivitis

Intervention

Drug:
• Corsodyl Original Dentifrice
It contains 67% weight/weight (w/w) Sodium Bicarbonate and 0.310% w/w Sodium Fluoride (1400 parts per million [ppm] Fluoride ion [F])
• Colgate Cavity Protection Dentifrice
It contains 0.76% w/w Sodium Monofluorophosphate (1000 ppm F) and 0.1% w/w Sodium Fluoride (450 ppm F)

Locations

Country	Name	City	State
United Kingdom	University of Bristol, Bristol Dental School and Hospital	Bristol

Sponsors (1)

Lead Sponsor	Collaborator
HALEON

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change from Baseline in Number of Bleeding Sites at Week 12	The bleeding will be assessed on the facial and lingual gingival surfaces of each scorable tooth. The gingivae will be air dried and then the examiner will use probe to assess bleeding. The probe will be gently inserted into the gingival crevice to a depth of approximately 1 millimeter (mm) and then run around the tooth. Change from baseline will be calculated as number of bleeding sites at Week 12 minus number of bleeding sites at baseline.	Baseline and Week 12
Secondary	Number of Bleeding Sites at Week 12, Compared to Negative Control	The bleeding will be assessed on the facial and lingual gingival surfaces of each scorable tooth. The gingivae will be air dried and then the examiner will use probe to assess bleeding. The probe will be gently inserted into the gingival crevice to a depth of approximately 1 mm and then run around the tooth.	Week 12
Secondary	Change from Baseline in Number of Bleeding Sites at Weeks 3 and 6	The bleeding will be assessed on the facial and lingual gingival surfaces of each scorable tooth. The gingivae will be air dried and then the examiner will use probe to assess bleeding. The probe will be gently inserted into the gingival crevice to a depth of approximately 1 mm and then run around the tooth. Change from baseline will be calculated as number of bleeding sites at post-baseline timepoints minus number of bleeding sites at baseline.	Baseline, Week 3, and Week 6
Secondary	Number of Bleeding Sites at Weeks 3 and 6, Compared to Negative Control	The bleeding will be assessed on the facial and lingual gingival surfaces of each scorable tooth. The gingivae will be air dried and then the examiner will use probe to assess bleeding. The probe will be gently inserted into the gingival crevice to a depth of approximately 1 mm and then run around the tooth. Change from baseline will be calculated as number of bleeding sites at post-baseline timepoints minus number of bleeding sites at baseline.	Week 3, and Week 6
Secondary	Change from Baseline in Mean Bleeding Index (BI) Score at Weeks 3, 6 and 12	The BI assesses the number of bleeding points elicited on probing as a measure of gingival condition. The gingivae will be air dried and then the examiner will use probe to assess bleeding. The probe will be gently inserted into the gingival crevice to a depth of approximately 1 mm and then run around the tooth. The BI will be assessed on the facial and lingual gingival surfaces of each scorable tooth on a 3-point scale ranging from 0 to 2, where 0= No bleeding after 30 seconds; 1= Bleeding observed within 30 seconds of probing; 2= Bleeding observed immediately on probing. Lower score indicates improvement. BI score= sum of index values over all evaluable tooth sites/Number of evaluable tooth sites. Change from baseline will be calculated as mean score at post-baseline timepoints minus score at baseline.	Baseline, Weeks 3, 6 and 12
Secondary	Mean BI Score at Weeks 3, 6 and 12, compared to negative control	The BI assesses the number of bleeding points elicited on probing as a measure of gingival condition. The gingivae will be air dried and then the examiner will use probe to assess bleeding. The probe will be gently inserted into the gingival crevice to a depth of approximately 1 mm and then run around the tooth. The BI will be assessed on the facial and lingual gingival surfaces of each scorable tooth on a 3-point scale ranging from 0 to 2, where 0= No bleeding after 30 seconds; 1= Bleeding observed within 30 seconds of probing; 2= Bleeding observed immediately on probing. Lower score indicates improvement. BI score= sum of index values over all evaluable tooth sites/Number of evaluable tooth sites.	Weeks 3, 6 and 12
Secondary	Change from Baseline in Mean Modified Gingival Index (MGI) Score at Weeks 3, 6 and 12	The MGI assessment is an evaluation of visual symptoms of gingivitis (for example, redness, texture, edema) on a 5-point scale ranging from 0 to 4, where 0= Absence of inflammation; 1= Mild inflammation; slight or little change in color, little change in texture of any portion of the marginal or papillary gingival unit; 2= Mild inflammation; criteria as above but involving the entire marginal or papillary gingival unit; 3= Moderate inflammation; glazing, redness, edema, and/ or hypertrophy of the marginal or papillary gingival unit; 4= Severe inflammation; marked redness, edema and/ or hypertrophy of the marginal or papillary gingival unit, spontaneous bleeding, congestion, or ulceration. Lower score indicates improvement. GMI score= Sum of index values over all evaluable tooth sites/Number of evaluable tooth sites. Change from baseline will be calculated as mean score at post-baseline timepoints minus score at baseline.	Baseline, Weeks 3, 6 and 12
Secondary	Mean MGI Score at Weeks 3, 6 and 12, Compared to Negative Control	The MGI assessment is an evaluation of visual symptoms of gingivitis (for example, redness, texture, edema) on a 5-point scale ranging from 0 to 4, where 0= absence of inflammation; 1= Mild inflammation; slight or little change in color, little change in texture of any portion of the marginal or papillary gingival unit; 2= Mild inflammation; criteria as above but involving the entire marginal or papillary gingival unit; 3= Moderate inflammation; glazing, redness, edema, and/ or hypertrophy of the marginal or papillary gingival unit; 4= Severe inflammation; marked redness, edema and/ or hypertrophy of the marginal or papillary gingival unit, spontaneous bleeding, congestion, or ulceration. Lower score indicates improvement. GMI score= Sum of index values over all evaluable tooth sites/Number of evaluable tooth sites.	Weeks 3, 6 and 12
Secondary	Change from Baseline in Mean Turesky Plaque Index (TPI) Score (Overall) at Weeks 3, 6 and 12	The TPI will be used to assess plaque on all gradable teeth. The plaque will first be disclosed using a plaque disclosing dye solution and the TPI will be assessed on the facial and lingual surfaces of each scorable tooth using a 6-point scale ranging from 0 to 5, where 0= No plaque; 1= Separate flecks of plaque at the cervical margin; 2= Thin continuous band of plaque (up to 1 mm) at the cervical margin; 3= Band of plaque wider than 1 mm but covering less than (<) 1/3 of the tooth surface; 4= Plaque covering more than or equal to (>=) 1/3 but < 2/3 of the tooth surface; 5= Plaque covering >= 2/3 of the tooth surface. Lower score indicates improvement. TPI score = Sum of index values over all evaluable tooth sites/Number of evaluable tooth sites. Change from baseline will be calculated as mean score at post-baseline timepoints minus score at baseline.	Baseline, Weeks 3, 6 and 12
Secondary	Mean TPI Score (Overall) at Weeks 3, 6 and 12, Compared to Negative Control	The TPI will be used to assess plaque on all gradable teeth. The plaque will first be disclosed using a plaque disclosing dye solution and the TPI will be assessed on the facial and lingual surfaces of each scorable tooth using a 6-point scale ranging from 0 to 5, where 0= No plaque; 1= Separate flecks of plaque at the cervical margin; 2= Thin continuous band of plaque (up to 1 mm) at the cervical margin; 3= Band of plaque wider than 1 mm but covering <1/3 of the tooth surface; 4= Plaque covering >=1/3 but <2/3 of the tooth surface; 5= Plaque covering >=2/3 of the tooth surface. Lower score indicates improvement. TPI score = Sum of index values over all evaluable tooth sites/Number of evaluable tooth sites.	Weeks 3, 6 and 12
Secondary	Change from Baseline in Mean TPI Score (Interproximal) at Weeks 3, 6 and 12	The TPI will be used to assess plaque on all gradable teeth. The plaque will first be disclosed using a plaque disclosing dye solution and the TPI will be assessed on the facial and lingual surfaces of each scorable tooth using a 6-point scale ranging from 0 to 5, where 0= No plaque; 1= Separate flecks of plaque at the cervical margin; 2= Thin continuous band of plaque (up to 1 mm) at the cervical margin; 3= Band of plaque wider than 1 mm but covering <1/3 of the tooth surface; 4= Plaque covering >=1/3 but <2/3 of the tooth surface; 5= Plaque covering >=2/3 of the tooth surface. Lower score indicates improvement. TPI score = Sum of index values over all evaluable tooth sites/Number of evaluable tooth sites. Change from baseline will be calculated as mean score at post-baseline timepoints minus score at baseline.	Baseline, Weeks 3, 6 and 12
Secondary	Mean TPI Score (Interproximal) at Weeks 3, 6 and 12, Compared to Negative Control	The TPI will be used to assess plaque on all gradable teeth. The plaque will first be disclosed using a plaque disclosing dye solution and the TPI will be assessed on the facial and lingual surfaces of each scorable tooth using a 6-point scale ranging from 0 to 5, where 0= No plaque; 1= Separate flecks of plaque at the cervical margin; 2= Thin continuous band of plaque (up to 1 mm) at the cervical margin; 3= Band of plaque wider than 1 mm but covering <1/3 of the tooth surface; 4= Plaque covering >=1/3 but <2/3 of the tooth surface; 5= Plaque covering >=2/3 of the tooth surface. Lower score indicates improvement. TPI score = Sum of index values over all evaluable tooth sites/Number of evaluable tooth sites.	Weeks 3, 6 and 12